BR112019006633A2 - combinações farmacêuticas de inibidor de histona desacetilase e inibidor de proteassoma ou fármaco imunomodulador para o tratamento de câncer hematológico - Google Patents

combinações farmacêuticas de inibidor de histona desacetilase e inibidor de proteassoma ou fármaco imunomodulador para o tratamento de câncer hematológico

Info

Publication number
BR112019006633A2
BR112019006633A2 BR112019006633A BR112019006633A BR112019006633A2 BR 112019006633 A2 BR112019006633 A2 BR 112019006633A2 BR 112019006633 A BR112019006633 A BR 112019006633A BR 112019006633 A BR112019006633 A BR 112019006633A BR 112019006633 A2 BR112019006633 A2 BR 112019006633A2
Authority
BR
Brazil
Prior art keywords
inhibitor
immunomodulatory drug
histone deacetylase
treatment
hematologic cancer
Prior art date
Application number
BR112019006633A
Other languages
English (en)
Inventor
Jin Kim Soo
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of BR112019006633A2 publication Critical patent/BR112019006633A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

a presente invenção refere-se a uma combinação farmacêutica para tratar um câncer hematológico compreendendo o inibidor de histona desacetilase (hdac) da fórmula química 1, um inibidor de proteassoma ou um fármaco imunomodulador e um agente anticâncer esteroidal em conjunto. a combinação farmacêutica da presente invenção pode ser útil para tratar um câncer hematológico, tal como mieloma múltiplo, reduzindo a toxicidade que o problema do inibidor convencional de hdac e exibindo um nível equivalente de efeitos farmacêuticos devido a um mecanismo inibidor complexo contra o câncer do composto de fórmula química 1 e o seu sal farmaceuticamente aceitável, o inibidor de proteassoma ou o fármaco imunomodulador e o agente anticâncer esteroidal.
BR112019006633A 2016-10-04 2017-09-29 combinações farmacêuticas de inibidor de histona desacetilase e inibidor de proteassoma ou fármaco imunomodulador para o tratamento de câncer hematológico BR112019006633A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160127767A KR102002581B1 (ko) 2016-10-04 2016-10-04 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물
PCT/KR2017/011015 WO2018066946A1 (en) 2016-10-04 2017-09-29 Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer

Publications (1)

Publication Number Publication Date
BR112019006633A2 true BR112019006633A2 (pt) 2019-07-02

Family

ID=61832016

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019006633A BR112019006633A2 (pt) 2016-10-04 2017-09-29 combinações farmacêuticas de inibidor de histona desacetilase e inibidor de proteassoma ou fármaco imunomodulador para o tratamento de câncer hematológico

Country Status (11)

Country Link
EP (1) EP3522891A4 (pt)
JP (2) JP2019529562A (pt)
KR (1) KR102002581B1 (pt)
CN (1) CN109789138A (pt)
AU (1) AU2017338564B2 (pt)
BR (1) BR112019006633A2 (pt)
CA (1) CA3038019A1 (pt)
MX (1) MX2019003907A (pt)
RU (1) RU2721409C1 (pt)
WO (1) WO2018066946A1 (pt)
ZA (1) ZA201902340B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7415973B2 (ja) 2021-02-12 2024-01-17 信越化学工業株式会社 化学増幅ポジ型レジスト組成物及びレジストパターン形成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010750A1 (en) * 2004-07-28 2006-02-02 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
EP1957056A2 (en) * 2005-11-10 2008-08-20 TopoTarget UK Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
EA020276B1 (ru) * 2006-09-15 2014-10-30 Янссен Фармацевтика Нв Ингибиторы гистоновых дезацетилаз с сочетанной активностью в отношении гистоновых дезацетилаз класса i и класса ii в комбинации с ингибиторами протеасом
WO2010085654A1 (en) * 2009-01-23 2010-07-29 Cancer Research Technology Limited Hedgehog pathway inhibitors
KR101168801B1 (ko) * 2009-03-27 2012-07-25 주식회사종근당 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
WO2010124009A2 (en) * 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
US8610434B2 (en) 2011-07-21 2013-12-17 ColdEdge Technologies, Inc. Cryogen-free cooling system for electron paramagnetic resonance system
WO2013021032A1 (en) * 2011-08-11 2013-02-14 Janssen Pharmaceutica Nv Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone
CN108245518B (zh) * 2012-08-09 2021-08-31 细胞基因公司 利用3-(4-((4-(吗啉代甲基)苯甲基)氧基)-1-氧代异二氢吲哚-2-基)哌啶-2,6- 二酮治疗癌症的方法
PE20161342A1 (es) * 2013-10-11 2016-12-31 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
CN105940001B (zh) * 2013-12-12 2018-02-06 株式会社钟根堂 作为选择性组蛋白脱乙酰酶(hdac)抑制剂的新型氮杂吲哚衍生物及包含其的药物组合物

Also Published As

Publication number Publication date
CA3038019A1 (en) 2018-04-12
EP3522891A4 (en) 2020-04-15
RU2721409C1 (ru) 2020-05-19
EP3522891A1 (en) 2019-08-14
WO2018066946A1 (en) 2018-04-12
KR102002581B1 (ko) 2019-07-22
CN109789138A (zh) 2019-05-21
JP2021020953A (ja) 2021-02-18
AU2017338564B2 (en) 2020-07-09
KR20180037507A (ko) 2018-04-12
AU2017338564A1 (en) 2019-05-02
ZA201902340B (en) 2020-08-26
MX2019003907A (es) 2019-08-05
JP2019529562A (ja) 2019-10-17

Similar Documents

Publication Publication Date Title
BR112021009595A2 (pt) Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres
SV2018005742A (es) Inhibidores de mcl-1 macrocíclicos para tratar el cáncer
CO2019008487A2 (es) Compuesto de quinazolina
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112017027951A2 (pt) composto inibitório de brk
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
MX2019003397A (es) Metodos para tratar trastornos mitocondriales y metabolicos.
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
BR112012025390A2 (pt) composto de tetraidrobenzotiofeno
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
CR20150505A (es) Derivado de dihidropiridazin-3,5-diona
MY183327A (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
BR112017023164A2 (pt) composto, e, método de prevenir e/ou tratar a esteato-hepatite não alcoólica em um indivíduo em necessidade do mesmo
BR112016027435A2 (pt) formulação inovadora de meloxicam
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
BR112015026840A2 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto, e, método prevenir ou tratar hiperfosfatemia
BR112017001803A2 (pt) aril-hidrazidas contendo uma fração de 2-piridona como agentes antibacterianos seletivos
BR112019008698A2 (pt) método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica
BR112019006633A2 (pt) combinações farmacêuticas de inibidor de histona desacetilase e inibidor de proteassoma ou fármaco imunomodulador para o tratamento de câncer hematológico
MX2019012522A (es) Compuestos y metodos terapeuticos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]